Y-Intercept (HK)’s Ascendis Pharma A/S ASND Stock Holding History

Y-Intercept (HK)’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,034	Closed	-$1.29M	–	1541
2025 Q4	$1.29M	Sell	6,034 -2,025	-25%	-$418K	0.03%	857
2025 Q3	$1.6M	Buy	8,059 +4,108	+104%	+$766K	0.04%	738
2025 Q2	$682K	Buy	+3,951	New	+$644K	0.02%	1088
2024 Q4	–	Sell	-5,931	Closed	-$886K	–	1166
2024 Q3	$886K	Buy	+5,931	New	+$801K	0.05%	500
2024 Q2	–	Sell	-1,406	Closed	-$213K	–	1378
2024 Q1	$213K	Sell	1,406 -12,696	-90%	-$1.81M	0.02%	1129
2023 Q4	$1.78M	Buy	+14,102	New	+$1.41M	0.17%	156
2023 Q1	–	Sell	-1,764	Closed	-$215K	–	1165
2022 Q4	$215K	Sell	1,764 -1,114	-39%	-$129K	0.03%	799
2022 Q3	$297K	Buy	+2,878	New	+$273K	0.03%	703

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Y-Intercept (HK)'s ASND Position: Q1 2026 in Review

Y-Intercept (HK) sold out of Ascendis Pharma A/S (ASND) in Q1 2026, closing a stake of 6,034 shares — an estimated $1.29M sold.

Y-Intercept (HK) first reported a position in ASND in Q3 2022 and held it in 8 quarters. The position peaked at $1.78M in Q4 2023. 274 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Y-Intercept (HK) reported no remaining Ascendis Pharma A/S position as of Q1 2026 after selling out during the quarter.
Y-Intercept (HK) sold 6,034 Ascendis Pharma A/S shares in Q1 2026, an estimated $1.29M.
Y-Intercept (HK) first reported a position in Ascendis Pharma A/S in Q3 2022 and held it in 8 quarters.
Y-Intercept (HK)'s Ascendis Pharma A/S position peaked at $1.78M in Q4 2023.
274 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Y-Intercept (HK)'s 13F filing for Q1 2026, filed 27 Apr 2026.